Proceedings of the Expert Consensus Group Meeting on Meningococcal Serogroup B Disease Burden and Prevention in India

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2022 Mar 3

PMID 35239455

Authors

Anand P Dubey

Rashna Dass Hazarika

Veronique Abitbol

Shafi Kolhapure

Someya Agrawal

Affiliations

Soon will be listed here.

Abstract

Meningococcal disease is highly transmissible, life-threatening and leaves significant sequelae in survivors. Every year, India, which has a plethora of risk factors for meningococcal disease, reports around 3000 endemic cases. However, the overall disease burden and serogroup distribution are unknown, creating a setting of general disease negligence and unawareness. Vaccination with quadrivalent meningococcal conjugate vaccine A, C, W, and Y is only recommended for high-risk children, and there is no overall guidance for meningococcal serogroup B (MenB) vaccination. MenB vaccines, which recently have been licensed in many countries but not in India, have significantly aided the fight against meningococcal disease. However, these MenB vaccines are not available in India. An Expert Consensus Group meeting was held with leading meningococcal disease experts to better understand the current disease epidemiology, particularly serogroup B, the prevalence gaps, and feasible ways to bridge them. The proceedings are presented in this paper.

References

. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1345-1422. PMC: 5614451. DOI: 10.1016/S0140-6736(17)32366-8. View

Mohammed I, Iliyasu G, Habib A . Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa. Pathog Glob Health. 2017; 111(1):1-6. PMC: 5375607. DOI: 10.1080/20477724.2016.1274068. View

Gorthi S, Nagpal A . Meningococcal Vaccine: Which, When and for Whom?. Med J Armed Forces India. 2016; 66(1):2-3. PMC: 4920903. DOI: 10.1016/S0377-1237(10)80081-4. View

Andrews S, Pollard A . A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. Lancet Infect Dis. 2014; 14(5):426-34. DOI: 10.1016/S1473-3099(13)70341-4. View

Khilnani G, Tiwari P . Air pollution in India and related adverse respiratory health effects: past, present, and future directions. Curr Opin Pulm Med. 2018; 24(2):108-116. DOI: 10.1097/MCP.0000000000000463. View

Aggarwal M, Manchanda V, Talukdar B . Meningitis due to Neisseria meningitidis serogroup B in India. Indian Pediatr. 2013; 50(6):601-3. View

LaForce F, Djingarey M, Viviani S, Preziosi M . Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps. Hum Vaccin Immunother. 2017; 14(5):1098-1102. PMC: 5989906. DOI: 10.1080/21645515.2017.1378841. View

Yezli S, Assiri A, Alhakeem R, Turkistani A, Alotaibi B . Meningococcal disease during the Hajj and Umrah mass gatherings. Int J Infect Dis. 2016; 47:60-4. DOI: 10.1016/j.ijid.2016.04.007. View

Yezli S, Wilder-Smith A, Saeed A . Carriage of Neisseria meningitidis in the Hajj and Umrah mass gatherings. Int J Infect Dis. 2015; 47:65-70. DOI: 10.1016/j.ijid.2015.11.014. View

10.

Rivero-Calle I, Raguindin P, Gomez-Rial J, Rodriguez-Tenreiro C, Martinon-Torres F . Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Serogroup B. Infect Drug Resist. 2019; 12:3169-3188. PMC: 6793463. DOI: 10.2147/IDR.S159952. View

11.

Burman C, Serra L, Nuttens C, Presa J, Balmer P, York L . Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Hum Vaccin Immunother. 2018; 15(2):459-469. PMC: 6422514. DOI: 10.1080/21645515.2018.1528831. View

12.

Smith I, Bjornevik A, Augland I, Berstad A, Wentzel-Larsen T, Halstensen A . Variations in case fatality and fatality risk factors of meningococcal disease in Western Norway, 1985-2002. Epidemiol Infect. 2006; 134(1):103-10. PMC: 2870352. DOI: 10.1017/S0950268805004553. View

13.

Koster-Rasmussen R, Korshin A, Meyer C . Antibiotic treatment delay and outcome in acute bacterial meningitis. J Infect. 2008; 57(6):449-54. DOI: 10.1016/j.jinf.2008.09.033. View

14.

Devi U, Mahanta J . Neonatal meningitis due to Neisseria meningitidis serogroup Y. Indian Pediatr. 2014; 51(9):757. View

15.

. Recommended adult immunization schedule for ages 19 years or older: United States, 2021. JAAPA. 2021; 34(4):1-18. DOI: 10.1097/01.JAA.0000735776.11981.1e. View

16.

Lucidarme J, Scott K, Ure R, Smith A, Lindsay D, Stenmark B . An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015. Euro Surveill. 2016; 21(45). PMC: 5144941. DOI: 10.2807/1560-7917.ES.2016.21.45.30395. View

17.

. The impact of air pollution on deaths, disease burden, and life expectancy across the states of India: the Global Burden of Disease Study 2017. Lancet Planet Health. 2018; 3(1):e26-e39. PMC: 6358127. DOI: 10.1016/S2542-5196(18)30261-4. View

18.

Pizza M, Bekkat-Berkani R, Rappuoli R . Vaccines against Meningococcal Diseases. Microorganisms. 2020; 8(10). PMC: 7601370. DOI: 10.3390/microorganisms8101521. View

19.

Halperin S, Bettinger J, Greenwood B, Harrison L, Jelfs J, Ladhani S . The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2011; 30 Suppl 2:B26-36. DOI: 10.1016/j.vaccine.2011.12.032. View

20.

John T, Gupta S, Chitkara A, Dutta A, Borrow R . An overview of meningococcal disease in India: knowledge gaps and potential solutions. Vaccine. 2013; 31(25):2731-7. DOI: 10.1016/j.vaccine.2013.04.003. View